An interleukin-15 superagonist with BCG - A major therapeutic advancement or just a small step in the right direction? Editorial
| Authors: | Pietzak, E. J.; Herr, H. W. |
| Title: | An interleukin-15 superagonist with BCG - A major therapeutic advancement or just a small step in the right direction? |
| Abstract: | For more than 40 years, intravesical Bacillus Calmette-Guérin (BCG) has remained the most effective treatment for non-muscle-invasive bladder cancer (NMIBC); however, tumor recurrence and progression are common, especially for those patients with carcinoma in situ (CIS). Therapeutic options are limited when treatment with BCG fails, and radical cystectomy remains the only curative treatment. BCG-unresponsive NMIBC criteria were developed in 2015 to identify patients for whom additional BCG would likely not be effective and to facilitate clinical trials of novel therapies. |
| Keywords: | carcinoma in situ; cystectomy; administration, intravesical; interleukins -- therapeutic use; antineoplastic agents, combined; bcg vaccine -- therapeutic use; non-muscle invasive bladder neoplasms -- drug therapy |
| Journal Title: | NEJM Evidence |
| Volume: | 2 |
| Issue: | 1 |
| ISSN: | 2766-5526 |
| Publisher: | Massachusetts Medical Society |
| Date Published: | 2023-01-01 |
| Language: | English |
| DOI: | 10.1056/EVIDe2200264 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Accession Number: 161096972 -- Entry Date: 20230130 -- Revision Date: 20230130 -- Publication Type: Article. -- Source: Cinahl |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work